Thanks Big Daniel. I agree with your assessment and hope December is a transformative month for PTX.
I find I amazing that PTX’s market cap is still only 10% of IMU’s. My only explanation for this 90% discount is that PTX has much lower liquidity in its stock, no institutional shareholder support and therefore primarily traded by retail investors.
Given the probable short time line until a US FDA registration study for PTX-100 and the rosy prospects of commercializtion of CellPryme as its use in a rapidly growing CAR-T industry expands, I would expect this discount to narrow significantly next year.
